Investors

  • 2021-08-30
    VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE
  • 2021-08-30
    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021
  • 2021-08-26
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON THE FIRST PERSON DOSED IN GLOBAL PHASE 3 REGISTRATION TRIAL OF SACITUZUMAB GOVITECAN-HZIY IN CHINA FOR METASTATIC UROTHELIAL CANCER
  • 2021-08-16
    DATE OF BOARD MEETING
  • 2021-08-06
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED JULY 31, 2021
  • 2021-08-05
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON APPROVAL OF CLINICAL TRIAL APPLICATION BY CHINA NMPA FOR PHASE 3 TRIAL OF XERAVATM FOR COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA
  • 2021-07-29
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON TAIWAN FDA GRANTING PEDIATRIC AND RARE SEVERE DISEASE PRIORITY REVIEW DESIGNATION FOR SACITUZUMAB GOVITECAN-HZIY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER
  • 2021-07-20
    VOLUNTARY ANNOUNCEMENT STRATEGIC COLLABORATION WITH MEDITRUST HEALTH CO., LTD TO DEVELOP NOVEL PAYMENT SOLUTIONS FOR PATIENTS IN CHINA
  • 2021-07-15
    1) GRANT OF SHARE OPTIONS, (2) GRANT OF SHARE AWARDS, (3) NON-EXEMPT CONNECTED TRANSACTION -- PROPOSED GRANT OF SHARE AWARDS TO CONNECTED PERSONS, AND (4) PROPOSED FUTURE AWARD GRANTS
  • 2021-07-13
    VOLUNTARY ANNOUNCEMENT STRATEGIC COLLABORATION WITH MEDBANKS HEALTH TECHNOLOGY CO., LTD TO DEVELOP INNOVATIVE HEALTHCARE SERVICE SOLUTIONS FOR PARTIENTS IN CHINA
 Copyright Everest Medicines 2020  云顶药业(苏州)有限公司 苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers

沪公网安备 31010602006477号